Treatment of Resistant Alopecia areata with Tofacitinib

Int J Trichology. 2022 Mar-Apr;14(2):60-61. doi: 10.4103/ijt.ijt_128_21. Epub 2022 Apr 4.

Abstract

The activity of tofacitinib for Alopecia areata (AA) has been reported but mainly from the western countries. We report the case of a young female Indian patient with AA unresponsive to therapy. Improvements in terms of hair regrowth were observed within 2 months of treatment with oral tofacitinib 5 mg BID tablets. The effectiveness of tofacitinib in hair regrowth was maintained till 5-month follow-up period. There were no side effects reported and the treatment with tofacitinib was well-tolerated.

Keywords: 5 mg BID; Alopecia areata; tofacitinib.

Publication types

  • Case Reports